STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical firm targeted on extreme uncommon ailments and most cancers, at the moment introduced the appointment of Martin Mackay, Ph.D. to the Firm’s Board of Administrators. Dr. Mackay is a extremely achieved analysis and growth (R&D) govt with greater than 30 years of pharmaceutical and biotech R&D expertise, together with management roles at Pfizer , AstraZeneca (NASDAQ:) and Alexion (NASDAQ:).
Martin is a confirmed trade chief whose expertise in growing and delivering novel therapies to sufferers in want is phenomenal, stated Saqib Islam, Chief Govt Officer of SpringWorks. His experience in uncommon ailments and distinctive views main a number of Analysis and Improvement organizations throughout the globe can be extraordinarily useful to SpringWorks as we advance and develop our pipeline and execute on our mission to make a significant distinction in sufferers’ lives. I’m delighted to welcome Martin to the SpringWorks group.
I’m very happy to affix the SpringWorks Board and work with a bunch of gifted and visionary leaders who’re pushed by a joint mission to develop and ship transformative therapies for sufferers with devastating ailments, stated Dr. Mackay. I imagine SpringWorks is uniquely positioned to make a big influence in therapeutic areas with large potential, and it’s an honor to convey my expertise and information to assist the essential work that SpringWorks is doing.
Dr. Mackay is a co-founder and Govt Chairman of Rallybio, a privately held clinical-stage biotechnology firm targeted on extreme uncommon ailments that was integrated in January 2018. Beforehand, Dr. Mackay was Govt Vice President, Head of Analysis and Improvement at Alexion from 2013 till 2017. Previous to becoming a member of Alexion, Dr. Mackay served as President, Analysis and Improvement at AstraZeneca from 2010 to 2013, the place he led the R&D features worldwide, together with discovery analysis, scientific growth, regulatory affairs, and key associated R&D features. From 1995 to 2009, he held varied positions at Pfizer Inc. (NYSE:), together with Senior Vice President of Worldwide Improvement, the place he was a member of the Govt Management Group and led a worldwide group tasked with advancing a portfolio of investigational medicines throughout a spread of illness areas, and President, Head of Pfizer Pharmatherapeutics, R&D, the place he oversaw all features of small molecule discovery and growth throughout a number of therapeutic areas. From 1986 to 1995, Dr. Mackay labored at Ciba-Geigy (now Novartis (SIX:)) in the UK and Switzerland, and held varied positions in tutorial analysis previous to that point. Dr. Mackay is at present a member of the Board of Administrators of Charles River Laboratories and Novo Nordisk (NYSE:). He acquired a First-Class Honours Diploma in microbiology from Heriot-Watt College and his Ph.D. in molecular genetics from the College of Edinburgh.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical firm making use of a precision medication method to growing and delivering life-changing medicines for individuals with extreme uncommon ailments and most cancers. OGSIVEO ® (nirogacestat), accredited in the US for the therapy of grownup sufferers with progressing desmoid tumors who require systemic therapy, is the Firm’s first FDA-approved remedy. SpringWorks additionally has a diversified focused remedy pipeline spanning stable tumors and hematological cancers, with applications starting from preclinical growth by superior scientific trials. Along with its wholly owned applications, SpringWorks has additionally entered into a number of collaborations with innovators in trade and academia to unlock the complete potential for its portfolio and create extra options for sufferers in want.
For extra info, go to www.springworkstx.com and observe @SpringWorksTx on X (previously Twitter), LinkedIn, and YouTube.
Contacts:
Kim Diamond
Vice President, Communications and Investor Relations
Cellphone: 203-561-1646
E-mail: kdiamond@springworkstx.com
Samantha Hilson Sandler
Senior Director, Investor Relations
Cellphone: 203-461-5501
E-mail: samantha.sandler@springworkstx.com
Supply: SpringWorks Therapeutics, Inc.
